>>VACAVILLE, CA--(MARKET WIRE)--Apr 27, 2004 -- At the 56th Annual American Academy of Neurology Meeting in San Francisco, California, Large Scale Biology Corporation (NasdaqNM:LSBC - News) announced today further progress through its wholly-owned subsidiary, Eclipse Diagnostics, Inc., in the development of its proprietary BAMF(TM) Technology for the early diagnosis of life-threatening disease.
In an ongoing collaboration, researchers at Wake Forest University Baptist Medical Center and Eclipse Diagnostics, Inc., using the BAMF(TM) Technology, have reported the presence of distinct proteomic signatures in blood serum from multiple sclerosis patients. The results, entitled, "A Blood Test to Diagnose Multiple Sclerosis: Use of MALDI/TOF and Serum Proteomic Pattern Analysis," were presented today at the meeting and is co-authored by Jagannadha R. Avasarala, M.D., Ph.D. of Wake Forest University and Gary M. Wolfe, Ph.D., Senior Vice President and Chief Scientific Officer, Eclipse Diagnostics, Inc.
Kevin J. Ryan, President and CEO of LSBC, stated, "These findings are further confirmation in our belief that Eclipse Diagnostics, Inc. proprietary BAMF(TM) Technology will lead to early diagnosis of diseases such as multiple sclerosis and various cancers and thus lead to improved patient outcomes through earlier medical intervention."
Further information about BAMF(TM) Technology can be found on the company's website (www.eclipsediagnostics.com).<<
snip
Cheers, Tuck |
